MedPath

Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized explorative double-blind placebo-controlled trial.

Phase 1
Conditions
(very early) systemic sclerosis
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Registration Number
EUCTR2015-004613-24-BE
Lead Sponsor
Radboudumc
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
30
Inclusion Criteria

- Age = 18 years

- Fulfilling VEDOSS criteria:
Raynauds' Phenomenon and
Positive for disease specific auto antibodies and
Systemic sclerosis specific nail fold capillaroscopic findings

- Puffy fingers < 3 years duration

- Modified Rodnan Skin Score = 0

- Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 0

Exclusion Criteria

- Presence of acrosclerosis, acrosteolysis and digital ulcers

- Presence of anti-RNA polymerase III auto antibodies

- Previous systemic treatment for SSc, namely methotrexate, prednisone (> 14 days in previous 6 months), mofetyl mycophenolate and cyclophosphamide

- Clinically significant internal organ involvement: DLCO < 80% predicted, VC < 70% predicted, renal dysfunction with GFR < 60 ml/min, diastolic dysfunction > grade 1 on echocardiography, pulmonary hypertension, weight loss > 10% in the last 6 months with unknown cause

- Usage of medication that influences CYP3A4 (eg carbamazepine / fenobarbital / fenytoïne / rifampicine/itraconazol e/ claritromycine / erytromycine / HIV – proteaseinhibitors) and hypersensitivity for methylprednisolone

- Contra-indications for methylprednisolone, such as pregnancy, lactation, psychotic or depressive disorder, ulcus duodeni or ventriculi, untreated hypertension (> 160-90 mmHg) or acute infections

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath